Hanna Rosenheck
Overview
Explore the profile of Hanna Rosenheck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
58
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumarasamy V, Wang J, Roti M, Wan Y, Dommer A, Rosenheck H, et al.
Nat Commun
. 2025 Feb;
16(1):1476.
PMID: 39924553
Cyclin dependent kinase 2 (CDK2) regulates cell cycle and is an emerging target for cancer therapy. There are relatively small numbers of tumor models that exhibit strong dependence on CDK2...
2.
Farrugia M, Repasky E, Chen M, Attwood K, Catalfamo K, Rosenheck H, et al.
Cancer Immunol Immunother
. 2025 Jan;
74(2):57.
PMID: 39751903
Background: Esophageal cancer (ESC) is an aggressive disease which often presents at an advanced stage. Despite trimodal therapy, 40-50% patients can develop metastatic disease by 18 months. Identification of patients...
3.
Kumarasamy V, Wang J, Frangou C, Wan Y, Dynka A, Rosenheck H, et al.
Cancer Res
. 2024 Jan;
84(7):1115-1132.
PMID: 38294344
Significance: Pharmacologic inhibition of KRAS elicits varied responses in pancreatic cancer 2D cell lines, 3D organoid cultures, and xenografts, underscoring the importance of mechanotransduction and the tumor microenvironment in regulating...
4.
Kumarasamy V, Frangou C, Wang J, Wan Y, Dynka A, Rosenheck H, et al.
bioRxiv
. 2023 May;
PMID: 37162905
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease for which new therapeutic interventions are needed. Here we assessed the cellular response to pharmacological KRAS inhibition, which target the central oncogenic...
5.
Mohammadpour H, Tsuji T, MacDonald C, Sarow J, Rosenheck H, Daneshmandi S, et al.
Cell Rep
. 2023 Mar;
42(3):112250.
PMID: 36924493
Abundant donor cytotoxic T cells that attack normal host organs remain a major problem for patients receiving allogeneic hematopoietic cell transplantation (allo-HCT). Despite an increase in our knowledge of the...
6.
Kumarasamy V, Nambiar R, Wang J, Rosenheck H, Witkiewicz A, Knudsen E
Oncogene
. 2022 Jun;
41(27):3524-3538.
PMID: 35676324
The management of metastatic estrogen receptor (ER) positive HER2 negative breast cancer (ER+) has improved; however, therapeutic resistance and disease progression emerges in majority of cases. Using unbiased approaches, as...
7.
Knudsen E, Kumarasamy V, Nambiar R, Pearson J, Vail P, Rosenheck H, et al.
Cell Rep
. 2022 Mar;
38(9):110448.
PMID: 35235778
Progression through G1/S phase of the cell cycle is coordinated by cyclin-dependent kinase (CDK) activities. Here, we find that the requirement for different CDK activities and cyclins in driving cancer...